De effectiviteit van het hepatitis B vaccin bij kinderen geboren uit moeders met een inflammatoire darmziekte die anti-TNF hebben gebruikt tijdens de zwangerschap
Recruiting
- Conditions
- Hepatitis B vaccineChildren born to IBD mothersInflammatory Bowel DiseaseAnti-TNF
- Registration Number
- NL-OMON20411
- Lead Sponsor
- Erasmus University Medical Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Study group: children born to IBD mothers treated with anti-TNF (infliximab or adalimumab) during (part of) the pregnancy
- Control group: children born to IBD mothers not treated with anti-TNF (any other IBD medication)
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- incapacity to understand the informed consent
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method anti-HBs levels 4 weeks after last inoculation for HBV
- Secondary Outcome Measures
Name Time Method (if required) anti-HBs levels after HBV booster vaccine in case of primary non-immunity